Jane H.

Jane H. has a wealth of experience in the medical and pharmaceutical industries. Starting in 2005, they held the role of Group Medical Director at Genentech. In 2015, they moved to Acerta as Vice President, Head of Clinical Development, and then to BeiGene in 2016 as Chief Medical Officer, Hematology. In 2021, they became an Independent Board Director at Protara Therapeutics. In 2022, they were appointed President and Chief Medical Officer at Prelude Therapeutics and also took on the role of Independent Board Director at 858 Therapeutics.

Jane H. attended Stanford University and the University of Washington.